Molecular Evaluation of Interleukin-8, Interleukin-27, and Vascular Endothelial Growth Factor Expression in Prostate Cancer Patients
DOI:
https://doi.org/10.14500/aro.12718Keywords:
Angiogenesis, Interleukin-8,, Interleukin-27, Prostate cancer, Vascular endothelial growth factorAbstract
Globally, prostate cancer (PCa) is becoming more prevalent and lethal. The progression of PCa is linked to both inflammation and angiogenesis. Pro-inflammatory cytokines, interleukin (IL)-8) and vascular endothelial growth factor (VEGF), promote inflammation, angiogenesis, and PCa progression. On the other hand, IL-27 (IL-27) has antitumor effects, modulates immune system activity, and thus serves as a suppressor of tumor growth. In the Kurdistan Region of Iraq, there is limited evidence linking these cytokines and their gene polymorphisms to PCa. This case–control study included 50 PCa patients and 30 age-matched healthy controls. Serum levels of these three cytokines were evaluated by enzyme-linked immunosorbent assay, whereas PCR and Sanger sequencing were used to find polymorphisms in IL-8 (rs4073, rs2227306), IL-27 (rs153109), and VEGF (rs2010963) in formalin-fixed paraffinembedded tissue DNA. GeneMANIA was used to assess gene-gene interaction networks. Statistical analyses were performed using Mann–Whitney U tests. Patients with PCa showed elevated IL-8 and VEGF levels and reduced IL-27 levels compared to controls (p < 0.05). Multiple single-nucleotide polymorphisms were found in all target genes, several of which were new to the GenBank. Gene-network analysis revealed that these three cytokines are involved in shared inflammatory, immunomodulatory, and angiogenic pathways. This study shows that altered serum levels and gene polymorphisms of these three cytokines may be biomarkers for PCa diagnosis and progression. It underlines the molecular interplay between inflammatory and angiogenic mediators and supports further cytokine-based diagnostic and therapeutic research.
Downloads
References
Alsamraae, M., Costanzo-Garvey, D., Teply, B.A., Boyle, S., Sommerville, G., Herbert, Z.T., Morrissey, C., Dafferner, A.J., Abdalla, M.Y., Fallet, R.W., Kielian, T., Jensen-Smith, H., DeOliveira, E.I., Chen, K., Bettencourt, I.A., Wang, J.M., MeVicar, D.W., Keeley, T., Yu, F., and Cook, L.M., 2023. Androgen receptor inhibition suppresses anti-tumor neutrophil response against bone metastatic prostate cancer via regulation of TβRI expression. Cancer Letters, 579, p.216468. DOI: https://doi.org/10.1016/j.canlet.2023.216468
Archer, M., Dogra, N., and Kyprianou, N., 2020. Inflammation as a driver of prostate cancer metastasis and therapeutic resistance. Cancers (Basel), 12, p.2984. DOI: https://doi.org/10.3390/cancers12102984
Basagiannis, D., Zografou, S., Murphy, C., Fotsis, T., Morbidelli, L., Ziche, M., Bleck, C., Mercer, J., and Christoforidis, S., 2016. VEGF induces signalling and angiogenesis by directing VEGFR2 internalisation through macropinocytosis. Journal of Cell Science, 129, pp.4091-4104. DOI: https://doi.org/10.1242/jcs.188219
Berenguer, C.V., Pereira, F., Câmara, J.S., and Pereira, J.A., 2023. Underlying features of prostate cancer-statistics, risk factors, and emerging methods for its diagnosis. Current Oncology, 30, pp.2300-2321. DOI: https://doi.org/10.3390/curroncol30020178
Catena, R., Larzabal, L., Larrayoz, M., Molina, E., Hermida, J., Agorreta, J., Montes, R., Pio, R., Montuenga, L.M., and Calvo, A., 2010. VEGF121 b and VEGF165 b are weakly angiogenic isoforms of VEGF-A. Molecular Cancer, 9, p.320. DOI: https://doi.org/10.1186/1476-4598-9-320
Chen, C.H., Ho, C.H., Hu, S.W., Tzou, K.Y., Wang, Y.H, and Wu, C.C., 2020. Association between interleukin-8 rs4073 polymorphism and prostate cancer: A meta-analysis. Journal of the Formosan Medical Association, 119, pp.1201-1210. DOI: https://doi.org/10.1016/j.jfma.2019.10.016
Chen, K., Jiang, K., Tang, L., Chen, X., Hu, J., and Sun, F., 2021. Analysis of clinical trials on therapies for prostate cancer in mainland China and globally from 2010 to 2020. Frontiers in Oncology, 11, p.647110. DOI: https://doi.org/10.3389/fonc.2021.647110
Dahal, S., Chaudhary, P., Jung, Y.S., and Kim, J.A., 2023. MegakaryocyteDerived IL-8 acts as a paracrine factor for prostate cancer aggressiveness through CXCR2 activation and antagonistic AR downregulation. Biomolecules and Therapeutics, 31, pp.210-218. DOI: https://doi.org/10.4062/biomolther.2023.005
Denmeade, S.R., Litvinov, I., Sokoll, L.J., Lilja, H., and Isaacs, J.T., 2003. Prostate‐specific antigen (PSA) protein does not affect growth of prostate cancer cells in vitro or prostate cancer xenografts in vivo. The Prostate, 56, pp.45-53. DOI: https://doi.org/10.1002/pros.10213
Di Carlo, E., Sorrentino, C., Zorzoli, A., Di Meo, S., Tupone, M.G., Ognio, E., Mincione, G., and Airoldi, I., 2013. The antitumor potential of Interleukin-27 in prostate cancer. Oncotarget, 5, pp.10332-10341. DOI: https://doi.org/10.18632/oncotarget.1425
Elaimy, A.L., and Mercurio, A.M., 2018. Convergence of VEGF and YAP/TAZ signaling: Implications for angiogenesis and cancer biology. Science Signaling, 11, p.eaau1165. DOI: https://doi.org/10.1126/scisignal.aau1165
Ene, C., Nicolae, I., and Ene, C.D., 2023. Angiogenic systemic response to the hypoxic microenvironment in prostate tumorigenesis: A pilot study. Experimental and Therapeutic Medicine, 26, p.483. DOI: https://doi.org/10.3892/etm.2023.12182
Ferrer, F.A., Miller, L.J., Andrawis, R.I., Kurtzman, S.H., Albertsen, P.C., Laudone, V.P., and Kreutzer, D.L., 1998. Angiogenesis and prostate cancer: In vivo and in vitro expression of angiogenesis factors by prostate cancer cells. Urology, 51, pp.161-167. DOI: https://doi.org/10.1016/S0090-4295(97)00491-3
Franz, M., Rodriguez, H., Lopes, C., Zuberi, K., Montojo, J., Bader, G.D., and Morris, Q., 2018. GeneMANIA update 2018. Nucleic Acids Research, 46, pp.W60-W64. DOI: https://doi.org/10.1093/nar/gky311
Furriol, J., Wik, E., Aziz, S., Askeland, C., Knutsvik, G., and Akslen, L.A., 2024. VEGFA gene variants are associated with breast cancer progression. The Journal of Pathology: Clinical Research, 10, p.e12393. DOI: https://doi.org/10.1002/2056-4538.12393
Ghazy, A.A., and Alenzi, M.J., 2021. Relevance of interleukins 6 and 8 single nucleotide polymorphisms in prostate cancer: A multicenter study. Prostate Cancer, 2021, p.3825525. DOI: https://doi.org/10.1155/2021/3825525
Guo, Y., Zang, Y., Lv, L., Cai, F., Qian, T., Zhang, G., and Feng, Q., 2017. IL8 promotes proliferation and inhibition of apoptosis via STAT3/AKT/NFκB pathway in prostate cancer. Molecular Medicine Reports, 16, pp.9035-9042. DOI: https://doi.org/10.3892/mmr.2017.7747
He, W., Yan, L., Hu, D., Hao, J., Liou, Y.C., and Luo, G., 2025. Neutrophil heterogeneity and plasticity: Unveiling the multifaceted roles in health and disease. Medicine Communications, 6, p.e70063. DOI: https://doi.org/10.1002/mco2.70063
Karwan, M.A., Abdullah, O.S., Amin, A.M., Mohamed, Z.A., Hasan, B., Shekha, M., Najmuldeen, H.H., Rahman, F.M., Housein, Z., Salih, A.M., Mohammed A.S., Sulaiman, L.R., Barzingi, B.T., Mahmood, D., Othman, H.E.,… & Salihi, A., 2022. Cancer incidence in the Kurdistan region of Iraq: Results of a seven-year cancer registration in Erbil and Duhok Governorates. Asian Pacific Journal of Cancer Prevention, 23, pp.601-615. DOI: https://doi.org/10.31557/APJCP.2022.23.2.601
Kluetz, P.G., Figg, W.D., and Dahut, W.L., 2010. Angiogenesis inhibitors in the treatment of prostate cancer. Expert Opinion on Pharmacotherapy, 11, pp.233-247. DOI: https://doi.org/10.1517/14656560903451716
Kourko, O., Smyth, R., Cino, D., Seaver, K., Petes, C., Eo, S.Y., Basta, S., and Gee, K., 2019. Poly(I: C)-mediated death of human prostate cancer cell lines is induced by interleukin-27 treatment. Journal of Interferon and Cytokine Research, 39, pp.483-494. DOI: https://doi.org/10.1089/jir.2018.0166
Larsson, P., Syed Khaja, A.S., Semenas, J., Wang, T., Sarwar, M., Dizeyi, N., Simoulis, A., Hedblom, A., Wai, S.N., Ødum, N., Persson, J.L., 2020. The functional interlink between AR and MMP9/VEGF signaling axis is mediated through PIP5K1α/pAKT in prostate cancer. International Journal of Cancer, 146, pp.1686-1699. DOI: https://doi.org/10.1002/ijc.32607
Leach, D.A., Chatterjee, N., Spahr, K., De Almeida, G.S., Varela‐Carver, A., Shah, T.T., Winkler, M., Ahmed, H.U., and Bevan, C.L., 2025. Simultaneous inhibition of TRIM24 and TRIM28 sensitises prostate cancer cells to antiandrogen therapy, decreasing VEGF signalling and angiogenesis. Molecular Oncology. 19, pp.2797-2821. DOI: https://doi.org/10.1002/1878-0261.70065
Lilja, H., Ulmert, D., and Vickers, A.J., 2008. Prostate-specific antigen and prostate cancer: Prediction, detection and monitoring. Nature Reviews Cancer, 8, pp.268-278. DOI: https://doi.org/10.1038/nrc2351
Luo, Y., Yang, Z., Yu, Y., and Zhang, P., 2022. HIF1α lactylation enhances KIAA1199 transcription to promote angiogenesis and vasculogenic mimicry in prostate cancer. International Journal of Biological Macromolecules, 222, pp.2225-2243. DOI: https://doi.org/10.1016/j.ijbiomac.2022.10.014
Maleki, A.H., Rajabivahid, M., Khosh, E., Khanali, Z., Tahmasebi, S., and Ghorbi, M.D., 2025. Harnessing IL-27: Challenges and potential in cancer immunotherapy. Clinical and Experimental Medicine, 25, p.34. DOI: https://doi.org/10.1007/s10238-025-01562-w
McClelland, S., Maxwell, P.J., Branco, C., Barry, S.T., Eberlein, C., and Labonte, M.J., 2024a. Targeting IL-8 and its receptors in prostate cancer: Inflammation, stress response, and treatment resistance. Cancers (Basel), 16, p.2797.
McClelland, S., Maxwell, P.J., Branco, C., Barry, S.T., Eberlein, C., and Labonte, M.J., 2024b. Targeting IL-8 and its receptors in prostate cancer: Inflammation, stress response, and treatment resistance. Cancers (Basel), 16, p.2797. DOI: https://doi.org/10.3390/cancers16162797
Mirlekar, B., and Pylayeva-Gupta, Y., 2021. IL-12 family cytokines in cancer and immunotherapy. Cancers (Basel), 13, p.167. DOI: https://doi.org/10.3390/cancers13020167
Occhipinti, S., Mengozzi, G., Oderda, M., Zitella, A., Molinaro, L., Novelli, F., Giovarelli, M., and Gontero, P., 2021. Low levels of urinary PSA better identify prostate cancer patients. Cancers (Basel), 13, p.3570. DOI: https://doi.org/10.3390/cancers13143570
Rizo-Téllez, S.A., and Filep, J.G., 2024. Beyond host defense and tissue injury: The emerging role of neutrophils in tissue repair. American Journal of Physiology-Cell Physiology, 326, pp.C661-C683. DOI: https://doi.org/10.1152/ajpcell.00652.2023
Sarkar, C., Goswami, S., Basu, S., and Chakroborty, D., 2020. Angiogenesis inhibition in prostate cancer: An update. Cancers (Basel), 12, p.2382. DOI: https://doi.org/10.3390/cancers12092382
Schalken, J.A., 2004. Molecular and cellular prostate biology: Origin of prostatespecific antigen expression and implications for benign prostatic hyperplasia. BJU International, 93, pp.5-9. DOI: https://doi.org/10.1111/j.1464-410X.2003.04633.x
Schneider, R., Yaneva, T., Beauseigle, D., El‐Khoury, L., and Arbour, N., 2011. IL‐27 increases the proliferation and effector functions of human naive CD8+ T lymphocytes and promotes their development into Tc1 cells . European Journal of Immunology, 41, pp.47-59. DOI: https://doi.org/10.1002/eji.201040804
Siegel, R.L., Kratzer, T.B., Giaquinto, A.N., Sung, H., and Jemal, A., 2025. Cancer statistics, 2025. CA: A Cancer Journal for Clinicians, 75, pp.10-45. DOI: https://doi.org/10.3322/caac.21871
Veltri, R.W., Miller, M.C., Zhao, G., Ng, A., Marley, G.M., Wright G.L. Jr., Vessella, R.L., and Ralph, D., 1999. Interleukin-8 serum levels in patients with benign prostatic hyperplasia and prostate cancer. Urology, 53, pp.139-147. DOI: https://doi.org/10.1016/S0090-4295(98)00455-5
Venet, F., and Monneret, G., 2018. Advances in the understanding and treatment of sepsis-induced immunosuppression. Nature Reviews Nephrology, 14, pp.121-137. DOI: https://doi.org/10.1038/nrneph.2017.165
Watts, E.L., Perez-Cornago, A., Kothari, J., Allen, N.E., Travis, R.C., and Key, T.J., 2020. Haematological markers and prostate cancer risk: A prospective analysis in UK Biobank. Cancer Epidemiology, Biomarkers and Prevention, 29, pp.1615-1626. DOI: https://doi.org/10.1158/1055-9965.EPI-19-1525
Wong, S.Y., Haack, H., Crowley, D., Barry, M., Bronson, R.T., and Hynes, R.O., 2005. Tumor-secreted vascular endothelial growth factor-C is necessary for prostate cancer lymphangiogenesis, but lymphangiogenesis is unnecessary for lymph node metastasis. Cancer Research, 65, pp.9789-9798. DOI: https://doi.org/10.1158/0008-5472.CAN-05-0901
Wu, T.T.L., Wang, J.S., Jiann, B.P., Yu, C.C., Tsai, J.Y., Lin, J.T., and Huang, J.K., 2007. Expression of vascular endothelial growth factor in Taiwanese benign and malignant prostate tissues. Journal of the Chinese Medical Association, 70, pp.380-384. DOI: https://doi.org/10.1016/S1726-4901(08)70024-8
Zhang, Z., Zhou, B., Zhang, K., Song, Y., Zhang, L., and Xi, M., 2016. IL-27 suppresses SKOV3 cells proliferation by enhancing STAT3 and inhibiting the Akt signal pathway. Molecular Immunology, 78, pp.155-163. DOI: https://doi.org/10.1016/j.molimm.2016.09.014
Zolochevska, O., Diaz‐Quiñones, A.O., Ellis, J., and Figueiredo, M.L., 2013. Interleukin‐27 expression modifies prostate cancer cell crosstalk with bone and immune cells in vitro. Journal of Cellular Physiology, 228, pp.1127-1136. DOI: https://doi.org/10.1002/jcp.24265
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Jutyar I. Saber, Hiwa R. Fatah, Fikry A. Qadir
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Authors who choose to publish their work with Aro agree to the following terms:
-
Authors retain the copyright to their work and grant the journal the right of first publication. The work is simultaneously licensed under a Creative Commons Attribution License [CC BY-NC-SA 4.0]. This license allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
-
Authors have the freedom to enter into separate agreements for the non-exclusive distribution of the journal's published version of the work. This includes options such as posting it to an institutional repository or publishing it in a book, as long as proper acknowledgement is given to its initial publication in this journal.
-
Authors are encouraged to share and post their work online, including in institutional repositories or on their personal websites, both prior to and during the submission process. This practice can lead to productive exchanges and increase the visibility and citation of the published work.
By agreeing to these terms, authors acknowledge the importance of open access and the benefits it brings to the scholarly community.
Accepted 2026-01-17
Published 2026-04-10
ARO Journal is a scientific, peer-reviewed, periodical, and diamond OAJ that has no APC or ASC.